You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Human Bispecific antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors Trial in Guangzhou (MR001)

Not yet recruiting
  • Advanced Solid Tumors
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Nov 12, 2023

Colorectal Cancer Trial (Administration of CC-3)

Not yet recruiting
  • Colorectal Cancer
  • Administration of CC-3
  • (no location specified)
Aug 11, 2023

B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)

Active, not recruiting
  • B-Cell Lymphoma
  • Heidelberg, Victoria, Australia
  • +2 more
Jan 20, 2023

Advanced Solid Tumor Trial (ES014)

Withdrawn
  • Advanced Solid Tumor
  • (no location specified)
Jan 30, 2023

Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)

Not yet recruiting
  • Myeloproliferative Disorders
  • +3 more
  • (no location specified)
Nov 21, 2023

Hematological Malignancy, Solid Tumor Trial (OT-A201, IMids, Bevacizumab)

Not yet recruiting
  • Hematological Malignancy
  • Solid Tumor
  • (no location specified)
Apr 24, 2023

Metastatic Solid Tumors, Esophageal Cancer, NSCLC Trial in Houston, San Antonio, Toronto (M1231)

Recruiting
  • Metastatic Solid Tumors
  • +2 more
  • Houston, Texas
  • +2 more
Jul 29, 2022

Locally Advanced or Metastatic Solid Tumors, Squamous-cell NSCLC Trial in Shanghai, Xuzhou (HLX35)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Squamous-cell Non-small Cell Lung Cancer
  • Shanghai, China
  • +1 more
Jun 28, 2022

Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer Trial in Sydney, Hong Kong (ARB202)

Recruiting
  • Gastrointestinal Cancer
  • +5 more
  • Adelaide, Australia
  • +3 more
Dec 13, 2022

Advanced Solid Tumor Trial (EMB-09)

Not yet recruiting
  • Advanced Solid Tumor
  • EMB-09
  • (no location specified)
Feb 22, 2022

Hematological Malignancy, Lymphoma Trial in Canton (SG2501)

Recruiting
  • Hematological Malignancy
  • Lymphoma
  • Canton, Ohio
    Gabrail Cancer Center Research, LLC
Aug 3, 2022

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Advanced Cancer, Metastatic Cancer Trial in Spain (FS222)

Recruiting
  • Advanced Cancer
  • Metastatic Cancer
  • Pamplona, Navarra, Spain
  • +5 more
Mar 29, 2022

Solid Tumor Trial in Worldwide (PRS-344/S095012)

Recruiting
  • Solid Tumor
  • Huntersville, North Carolina
  • +10 more
Jun 29, 2022

HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

Not yet recruiting
  • HIV-1-infection
  • Mbeya, Tanzania
    National Institute for Medical Research-Mbeya Medical Resarch Ce
Jun 6, 2023

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)

Active, not recruiting
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Indianapolis, Indiana
  • +6 more
Aug 16, 2022

Advanced Malignant Tumors Lymphomas Trial in United States (IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody

Recruiting
  • Advanced Malignant Tumors Lymphomas
  • IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
  • Los Angeles, California
  • +3 more
Aug 23, 2022

NSCLC Metastatic, Gastric Cancer, Head Neck Cancer Trial in Orange, West Valley City (MCLA-129)

Recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • +2 more
  • Orange, California
  • +1 more
May 21, 2021

Breast Cancer, Uterine Cancer, Ovarian Cancer Trial in Denmark, France, Spain (GEN1047 is a bispecific antibody that induces

Recruiting
  • Breast Cancer
  • +3 more
  • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
  • Copenhagen, Denmark
  • +5 more
Jul 25, 2022

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer Trial in Detroit (biological,

Completed
  • Metastatic Pancreatic Adenocarcinoma
  • +3 more
  • Aldesleukin
  • +9 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Mar 30, 2022

Advanced Cancer, Metastatic Cancer Trial in Spain, United States (FS120)

Recruiting
  • Advanced Cancer
  • Metastatic Cancer
  • New Haven, Connecticut
  • +7 more
Aug 8, 2022

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck Trial in United States (FS118)

Recruiting
  • Advanced Cancer
  • +2 more
  • Los Angeles, California
  • +6 more
Mar 3, 2022

Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)

Terminated
  • Neuroblastoma
  • +2 more
  • Humanized 3F8 Bispecific Antibody
  • Blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 11, 2022

SCLC, Extensive Stage Trial in Shanghai (AK112, Etoposide, Carboplatin)

Recruiting
  • SCLC, Extensive Stage
  • Shanghai, Shanghai, China
    Shun Lu
Oct 12, 2022